Advertisement

CBRE Group, Inc. announced today that they have been hired to sell Eli Lilly’s biomanufacturing plant in Vacaville, California. The highly flexible and multi-purpose facility is one of the largest bulk API manufacturing facilities for recombinant microbial-based biopharmaceuticals in the U.S.

The site includes a 52-acre campus, with 28 acres available for future expansion. The 78,198-square-foot (7,265 square meter) facility includes a state-of-the-art downstream processing building, capable of handling complex purification steps; well-equipped analytical laboratories for raw materials, environmental monitoring and release testing, and a mechanical workshop for equipment maintenance and calibration. A 1 MW solar panel array on site provides low cost electric power to the facility.

CBRE Brokerage Services Life Sciences group will direct the marketing to U.S. and international biopharma firms.

Eli Lilly and Company is an American global pharmaceutical company with headquarters located in Indianapolis.

Advertisement
Advertisement